Yes, Paxlovid is fully FDA-approved for adults. The FDA granted full approval on May 25, 2023, for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progressing to severe illness, hospitalization, or death. For adolescents aged 12 to 17 (weighing at least 88 pounds), Paxlovid remains available under a separate emergency use authorization rather than full approval.
What Full Approval Means
Full FDA approval is a higher regulatory bar than emergency use authorization (EUA). An EUA allows a product to be used during a public health emergency based on limited evidence that the benefits likely outweigh the risks. Full approval requires a more complete review of clinical trial data, manufacturing quality, and labeling. Paxlovid initially entered the market under an EUA in December 2021, then cleared the full approval process about 18 months later.
In practical terms, the distinction matters less for patients than it does for regulatory confidence. Both pathways allow doctors to prescribe the drug, and insurance coverage applies under either status. But full approval signals that the FDA reviewed the complete dataset and confirmed the drug’s safety and effectiveness through its standard process.
Who Qualifies for Paxlovid
Paxlovid is specifically approved for adults with mild-to-moderate COVID-19 who face a higher risk of becoming seriously ill. The clinical trial that supported approval, known as EPIC-HR, enrolled patients 18 and older with at least one risk factor. Those risk factors included diabetes, a BMI over 25, chronic lung disease (including asthma), chronic kidney disease, cardiovascular disease, hypertension, active cancer, immunosuppressive conditions or treatments, sickle cell disease, neurodevelopmental disorders, and current smoking. Adults 60 and older qualified regardless of whether they had any other risk factor.
If you’re a generally healthy adult under 60 with no underlying conditions, Paxlovid isn’t indicated for you under the current approval. The drug was studied in, and approved for, a population where COVID-19 poses a meaningful threat of hospitalization.
How Well It Works
In the pivotal EPIC-HR trial, Paxlovid reduced the risk of COVID-related hospitalization or death by about 89% compared to placebo. That trial was conducted in unvaccinated, high-risk patients before the Omicron variant became dominant, which represents a population where the baseline risk of severe outcomes was relatively high. Real-world effectiveness in a more vaccinated, Omicron-era population is lower in absolute terms, but the drug still provides meaningful protection for high-risk individuals.
Treatment must start within five days of your first symptoms. The earlier you begin, the better. This is one of the most important practical details: if you test positive and have risk factors, the clock is already running.
How It Works
Paxlovid is actually two drugs packaged together. The first, nirmatrelvir, blocks an enzyme the virus needs to copy itself. Without that enzyme functioning, the virus can’t process the raw protein materials it requires for replication, and the infection stalls. The second component, ritonavir, doesn’t fight the virus directly. Instead, it slows your liver from breaking down nirmatrelvir too quickly, keeping blood levels of the active drug high enough to be effective. You take both together, twice a day, for five days.
Drug Interactions Are a Major Concern
The ritonavir component is the reason Paxlovid has an unusually long list of drug interactions. Because ritonavir affects how your liver processes many medications, it can cause dangerous spikes in the blood levels of other drugs you’re already taking. Some combinations are outright contraindicated, meaning they should never be used together.
The list of problem medications is broad. It includes certain heart rhythm drugs, cholesterol-lowering statins (specifically lovastatin and simvastatin), some blood pressure medications, sedatives like triazolam, certain seizure medications, migraine drugs, and specific immunosuppressants. The herbal supplement St. John’s Wort is also contraindicated because it has the opposite effect, reducing Paxlovid’s levels so much that the drug may not work.
Other medications don’t need to be permanently avoided but may require a temporary dose change or closer monitoring. These include blood thinners like warfarin and apixaban, the heart drug digoxin, certain antidepressants, calcium channel blockers, corticosteroids, hormonal contraceptives, and immunosuppressants like tacrolimus and cyclosporine. Your pharmacist or prescriber will review your full medication list before dispensing Paxlovid. If you take multiple prescriptions, this step is essential.
Dose Adjustments for Kidney Function
The standard dose is two nirmatrelvir tablets (300 mg total) plus one ritonavir tablet (100 mg), taken together twice daily. If you have moderate kidney impairment, the nirmatrelvir dose is cut in half: one tablet instead of two, while the ritonavir dose stays the same. Paxlovid is not recommended for people with severe kidney impairment.
COVID Rebound After Treatment
Some people experience a return of symptoms or a positive test after finishing their five-day course, a phenomenon often called “Paxlovid rebound.” This got significant media attention, but the clinical data tell a more nuanced story. In the original trials, viral rebound (measured by RNA levels, not necessarily symptoms) occurred in roughly 6% to 8% of people who took Paxlovid. However, it also occurred in about 6% to 7% of people who took a placebo. The difference between the two groups was not statistically significant in most analyses.
This suggests that some degree of viral fluctuation after acute COVID-19 is a natural part of the infection’s course, not something unique to Paxlovid. If you do experience rebound symptoms, they are typically mild and resolve on their own.
Cost and Access
Paxlovid carries a retail price that can run over $1,000 without assistance. For commercially insured patients, Pfizer’s PAXCESS savings program can reduce the out-of-pocket cost to as little as $0, with savings up to $1,500 per prescription. At certain pharmacies, an automatic discount brings the cost down to $25 before additional savings programs apply.
Through the end of 2024, a government-funded patient assistance program operated by Pfizer provided Paxlovid at no cost to patients on Medicare, Medicaid, TRICARE, VA Community Care, or those without insurance. Coverage details beyond that date depend on program renewals and your specific insurance plan, so it’s worth asking your pharmacy about current pricing when you fill the prescription.